Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1
(PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not …
(PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not …
Immune checkpoints in the tumor microenvironment
Interactions between immune checkpoints (ICs) and their ligands negatively regulate T cell
activation pathways involved in physiological immune responses against specific antigens …
activation pathways involved in physiological immune responses against specific antigens …
A Microenvironment Dual‐Responsive Nano‐Drug Equipped with PD‐L1 Blocking Peptide Triggers Immunogenic Pyroptosis for Prostate Cancer Self‐Synergistic …
H Wang, Z Gao, D Jiao, Y Zhang… - Advanced Functional …, 2023 - Wiley Online Library
Induction of immunogenic cell death (ICD) in tumor combined with immune checkpoint
blockade (ICB) therapy is widely developed to improve the efficacy of cancer …
blockade (ICB) therapy is widely developed to improve the efficacy of cancer …
Promoter DNA hypermethylation and paradoxical gene activation
DNA methylation is a stable epigenetic modification that contributes to the spatiotemporal
regulation of gene expression. The manner in which DNA methylation contributes to …
regulation of gene expression. The manner in which DNA methylation contributes to …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng, J Liu… - Advanced …, 2023 - Wiley Online Library
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
[HTML][HTML] Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy
Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in
cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by …
cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by …
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
K Choucair, S Morand, L Stanbery, G Edelman… - Cancer gene …, 2020 - nature.com
Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced
durable responses in many cancer types. However, there remains a subset of patients that …
durable responses in many cancer types. However, there remains a subset of patients that …
PD-1/PD-L1 and DNA damage response in cancer
M Kciuk, D Kołat, Ż Kałuzińska-Kołat, M Gawrysiak… - Cells, 2023 - mdpi.com
The application of immunotherapy for cancer treatment is rapidly becoming more
widespread. Immunotherapeutic agents are frequently combined with various types of …
widespread. Immunotherapeutic agents are frequently combined with various types of …
Gene regulation of intracellular adhesion molecule-1 (ICAM-1): A molecule with multiple functions
Abstract Intracellular adhesion molecule 1 (ICAM-1) is one of the most extensively studied
inducible cell adhesion molecules which is responsible for several immune functions like T …
inducible cell adhesion molecules which is responsible for several immune functions like T …
Recent findings in the regulation of programmed death ligand 1 expression
X Shen, L Zhang, J Li, Y Li, Y Wang, ZX Xu - Frontiers in immunology, 2019 - frontiersin.org
With the recent approvals for the application of monoclonal antibodies that target the well-
characterized immune checkpoints, immune therapy shows great potential against both …
characterized immune checkpoints, immune therapy shows great potential against both …